The Nutrigenetics of Hyperhomocysteinemia

QUANTITATIVE PROTEOMICS REVEALS DIFFERENCES IN THE METHIONINE CYCLE ENZYMES OF GENE-INDUCED VERSUS DIET-INDUCED HYPERHOMOCYSTEINEMIA

Patricia M. DiBello‡§, Sanjana Dayal¶, Suma Kaveti‡, Dongmei Zhang‡, Michael Kinter¶, Steven R. Lentz¶, and Donald W. Jacobsen‡§**‡‡

Hyperhomocysteinemia has long been associated with atherosclerosis and thrombosis and is an independent risk factor for cardiovascular disease. Its causes include both genetic and environmental factors. Although homocysteine is produced in every cell as an intermediate of the methionine cycle, the liver contributes the major portion found in circulation, and fatty liver is a common finding in homocystinuric patients. To understand the spectrum of proteins and associated pathways affected by hyperhomocysteinemia, we analyzed the mouse liver proteome of gene-induced (cystathionine $\beta$-synthase (CBS)) and diet-induced (high methionine) hyperhomocysteinemic mice using two-dimensional difference gel electrophoresis and Ingenuity Pathway Analysis. Nine proteins were identified whose expression was significantly changed in response to genotype and diet. Importantly, three enzymes of the methionine cycle were up-regulated. S-Adenosylhomocysteine hydrolase increased in response to genotype and/or diet, whereas glycine $N$-methyltransferase and betaine-homocysteine methyltransferase only increased in response to diet. The antioxidant proteins peroxiredoxins 1 and 2 increased in wild-type mice fed the high methionine diet but not in the CBS mutants, suggesting a dysregulation in the antioxidant capacity of those animals. Furthermore, thioredoxin 1 decreased in both wild-type and CBS mutants on the diet but not in the mutants fed a control diet. Several urea cycle proteins increased in both diet groups; however, arginase 1 decreased in the CBS$^{+/−}$ mice fed the control diet. Pathway analysis identified the retinoid X receptor signaling pathway as the top ranked network associated with the CBS$^{+/−}$ genotype, whereas xenobiotic metabolism and the NRF2-mediated oxidative stress response were associated with the high methionine diet. Our results show that hyperhomocysteinemia, whether caused by a genetic mutation or diet, alters the abundance of several liver proteins involved in homocysteine/methionine metabolism, the urea cycle, and antioxidant defense. Molecular & Cellular Proteomics 9:471–485, 2010.

Homocysteine (Hcy)$^1$ is a thiol-containing amino acid that is produced in every cell of the body as an intermediate of the methionine cycle (Fig. 1, Reactions 1–5) (1). Once formed, the catabolism of homocysteine occurs via three enzymatic pathways. 1) Hcy is remethylated back to methionine using vitamin B$_{12}$-dependent methionine synthase (Fig. 1, Reaction 4) and/or 2) betaine-homocysteine methyltransferase (BHMT) (Fig. 1, Reaction 5), and 3) Hcy is converted to cysteine via the transsulfuration pathway using CBS and $\gamma$-cystathionase (Fig. 1, Reactions 6 and 7). Under normal conditions ~40–50% of the Hcy that is produced in the liver is remethylated, ~40–50% is converted to cysteine, and a small amount is exported (1–3). However, when Hcy production is increased (i.e. increased dietary methionine/protein intake) or when Hcy catabolism is decreased (i.e. CBS deficiency or B vitamin deficiencies), excess Hcy is exported into the extracellular space, resulting in hyperhomocysteinemia (1–5).

Homocystinuria was first described in the 1960s by Carson et al. (6); they observed 10 pediatric patients with severely elevated levels of Hcy in the urine and hyperhomocystinemia. Normal concentrations of plasma total homocysteine ($t$Hcy) range from 5 to 12 $\mu$mol (7); however, in homocystinuria, $t$Hcy

---

$^1$ The abbreviations used are: Hcy, homocysteine; tHcy, plasma total homocysteine; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; CBS, cystathionine $\beta$-synthase; BHMT, betaine-homocysteine methyltransferase; GNMT, glycine $N$-methyltransferase; SAHH, S-adenosylhomocysteine hydrolase; NIT2, Nit protein 2; ARG1, arginase 1; ASL, argininosuccinate lyase; CPS1, carbamoyl-diphosphate synthetase 1; SELENBP1, selenoamino acid-binding protein 1; CNDP2, cytosolic nonspecific dipeptidase 2; PEPBP1, phosphatidylethanolamine-binding protein 1; ENO1, enolase 1; PRDX, peroxiredoxin; TXN, thioredoxin; EPHX2, epoxide hydrolase 2; HSP90AA, heat shock protein 90, $\alpha$; PSME1, proteosome 28 subunit $\alpha$; ALB, albumin; FABP1, fatty acid-binding protein 1; RXR, retinoid X receptor; NFR2, nuclear factor erythroid 2-related factor 2; GPx-1, glutathione peroxidase 1; NOS, nitric-oxide synthase; HM, high methionine; C, control; ROS, reactive oxygen species; NO, nitric oxide; 2-D, two-dimensional; IPA, Ingenuity Pathway Analysis; IS, internal standard.
levels can exceed 100 \( \mu M \). Homocystinuric patients present with mental retardation, abnormal bone growth, fine hair, malar flush, and dislocation of the lens of the eye, and most die from premature cardiovascular disease (6, 8). Autopsy findings indicate widespread thromboembolism, arteriosclerosis, and fatty livers (6, 8). Mudd et al. (9, 10) identified the cause of homocystinuria as a defect in the enzyme cystathionine \( \beta \)-synthase. A recent study of newborn infants in Denmark estimated the birth prevalence for CBS heterozygosity to be about 1:20,000 (11).

Plasma thcy concentrations are also directly correlated with dietary methionine/protein intake (12, 13). Guttormsen et al. (13) demonstrated that a protein-rich meal affected thcy for at least 8–24 h. When normal subjects were fed a low protein-containing breakfast (12–15 g), plasma methionine levels increased slightly after 2 h (22.5–27.5 \( \mu M \)), but thcy levels did not change significantly. However, when these same subjects were fed a high protein meal (52 g), plasma methionine levels peaked after 4 h (38 \( \mu M \)), and thcy rose steadily until a maximum level was reached 8 h postmeal (7.6 versus 8.5 \( \mu M \)) (13). Thus, the following questions can be raised. How does the hepatic proteome respond to a hyperhomocysteinemic diet, and are the changes that accompany such a diet the same as or different from those that may be observed in gene-induced hyperhomocysteinemia?

Because hyperhomocysteinemia is a strong independent risk factor for cardiovascular, cerebrovascular, and peripheral vascular disease, most of the current research has focused on the mechanisms involved in Hcy-induced endothelial dysfunction (14–24). The results of those studies have concluded that Hcy induces intracellular oxidative stress by generating ROS, which in turn lead to decreased bioavailable nitric oxide (NO), altered gene expression, increased endoplasmic reticulum stress, and activation of cholesterol biosynthesis. Also, several studies have examined the association between hyperhomocysteinemia and alcoholic liver disease, but few have looked at the effect of Hcy on the non-alcoholic liver even though fatty liver is a constant finding in homocystinuria (6, 8), and the liver is the major source of circulating Hcy (4, 5, 10).

We hypothesize that 1) the liver proteome will respond to hyperhomocysteinemia by altering the expression of proteins involved in methionine/homocysteine metabolism and antioxidant defense and that 2) the set of proteins that are expressed when hyperhomocysteinemia is induced by CBS deficiency will differ from those expressed as a result of a high methionine diet. In the present study, we use a well established mouse model of CBS deficiency to study the early changes in the liver proteome that accompany hyperhomocysteinemia (25).

**EXPERIMENTAL PROCEDURES**

**Animals**—Colonies of CBS-deficient mice (C57BL/6J background) (25) were bred and housed at the University of Iowa Animal Facilities. All protocols were approved by the University of Iowa’s Animal Care Committee. Four experimental groups of animals were studied: 1) wild-type CBS\(^{-/-}\) mice on a control (C) diet, 2) wild-type CBS\(^{-/-}\) mice fed a high methionine (HM) diet, 3) heterozygote CBS\(^{-/-}\) mice...
fed a C diet, and 4) heterozygote CBS+/− mice fed an HM diet. Each experimental group consisted of five to eight animals and included mice of both genders. Upon weaning (3–4 weeks of age), all animals were fed normal mouse chow (LM485, Harlan Teklad Inc., Madison, WI) for 2 weeks. A subgroup of CBS+/− and CBS−/− mice was administered 0.5% methionine in their drinking water ad libitum. After the 2-week treatment period, EDTA-plasma samples were obtained, the mice were sacrificed, and the livers were removed and snap frozen in liquid N2. One portion of each liver was used for proteomics analysis, and a second portion was used for the determinations of Hcy, Cys, GSH, and Cys-Gly.

Sample Preparation for Thiol Determinations and Thiol Stability—The livers were thawed and dissected into two pieces weighing ~100 mg each. The portion to be used for total intracellular thiol determinations was homogenized (100 mg of tissue/1 ml of homogenization buffer) in ice-cold 0.1 M KH2PO4 (pH 7.4) containing protease inhibitors (10 μg/ml soybean trypsin inhibitor, 0.6 mM PMSF, and 3.5 μg/ml aprotinin) for 20 s using a Tissue Tearor homogenizer set at 50% power. Following homogenization, a 100–200 μl aliquot of the SDS homogenate was removed and treated with the 2-D Clean-up kit (GE Healthcare) to remove SDS, salts, lipids, and nucleic acids and to quantitatively precipitate protein. The precipitated proteins were resuspended in 100–200 μl of CyDye labeling buffer (7 μl urea, 2 μl thiourea, 4% CHAPS, 50 mM Tris (pH 8.6), and protein concentration was determined using the 2-D Quant kit (GE Healthcare). Two-dimensional (2-D) DIGE—To detect protein differences between two experimental conditions (i.e., control versus diet or wild type versus mutant), a modified 2-D electrophoresis procedure was used (29). Equal amounts of the three CyDye-labeled samples (50 μg of Cy3-labeled sample, 50 μg of Cy5-labeled sample, and 50 μg of Cy2-labeled IS) were admixed, and DeStreak™ sample buffer (GE Healthcare) containing 1% amorpholites (pH 3–10) was added to the mixture to a final volume of 450 μl. Each analytical gel was loaded with 150 μg of total protein. A preparatory scale gel was loaded with 750 μg of unlabeled IS. IEF was carried out on 24-cm Immobiline DryStrips (pH 3–10 non-linear; GE Healthcare) using the Ettan IPGPhor II™ IEF apparatus (GE Healthcare). The sample (450 μl) was added to the IPG DryStrip and actively rehydrated for 11 h at 20 °C using 50 V and 50 μA/strip. Focusing was carried out at 20 °C using the following conditions: step 1: 0.5 h, 20–250 V; step 2: 0.5 h, 250–6000 V; step 3: 5 h, 6000 V; and step 4: 10 h, 6000 V for a total of 78 kV-h. After the focusing step, the strips were equilibrated in 50 mM Tris-HCl, 6 μl urea, 2% SDS, 30% glycerol, 2% DTT, 0.002% bromophenol blue (pH 8.8) for 10 min followed by a second 10-min equilibration step in 50 mM Tris-HCl, 6 μl urea, 2% SDS, 30% glycerol, 2% DTT, 0.002% bromophenol blue, 2% iodoacetamide (pH 8.8). The IPG strips were then electrophoresed on a 24-cm 12.5% precast SDS-polycrylamide gel (Jule Inc., Milford, CT) for 4 h at constant power (5 watts/strip for 1 h; 20 watts/strip for 3 h) in an Ettan DALT™/Twelve vertical electrophoresis system (GE Healthcare) using the Laemmli buffer system (30). The preparatory scale gel was fixed and stained with GelCode Blue™ Coomassie stain (Pierce).

Image Acquisition and DeCyder Analysis—The gels were analyzed by postrun fluorescence imaging using the Typhoon Trio™ imager (GE Healthcare). The Cy2 images were acquired with a 488 nm excitation laser and a 520 nm emission filter, the Cy3 images used a 532 nm excitation laser with a 580 nm emission filter, and the Cy5 images were acquired with a 633 nm excitation laser and a 670 nm emission filter. The Coomassie-stained preparatory gel was scanned with the Cy5 excitation laser (633 nm) without the use of an emission filter. The resolution was set to 200 μm. After the multiplexed images were loaded into the DeCyder software, the spot detection parameters were set as follows: Threshold: 0.25; Spot Intensity: 0.75; Spot Size: 200.00; Spot Width: 200.00; Spot Height: 200.00; Spot Gap: 50.00; and Spot Filling: 0.75.
were acquired, image analysis was performed using DeCyder™ 5.01 software (GE Healthcare) using both the “differential in-gel analysis” module and the “biological variation analysis” module. Protein spots exhibiting a statistically significant (p ≤ 0.05) 2-fold difference in intensity between experimental groups were excised from the preparatory gel and identified by LC-MS-MS as described by Kinter and Sherman (31).

2-D DIGE Validation—Although the manufacturer of the CyDyes reports that they are matched for charge and molecular weight, it was important to experimentally confirm 1) that labeling of any given protein with either of the CyDyes did not change the pl or mobility of that specific protein and 2) that the fluorescence output (pixel intensity) of each dye-labeled protein in co-detected spots was the same. To that end, five mouse liver homogenates were labeled with either Cy2, Cy3, or Cy5, and 2-D DIGE analysis was performed on each admixed sample. Additionally, the intra-assay coefficient of variation was determined by running three 2-D DIGE gels per sample on the same day, and the inter-assay coefficient of variation was determined by running three 2-D DIGE gels per sample on 2 different days. The Cy2 signal data were used for generating the coefficient of variation results.

Identification of Differentially Expressed Proteins by LC-Tandem Mass Spectrometry—The excised spots were minced into 1-mm³ pieces; destained in 50% ethanol, 5% acetic acid; and dehydrated with acetone. The dried gel pieces were digested with 5 µl of trypsin (20 µg/ml) in 50 mM ammonium bicarbonate for 18 h at 23 °C. The samples were microcentrifuged briefly and treated two times with 30 µl of 50% acetone, 5% formic acid to extract the peptides. The extracts were pooled and concentrated to <10 µl using a SpeedVac. The volume was readjusted to 30 µl with 1% acetic acid, and LC-MS-MS analysis was carried out directly on this sample. An linear trap quadrupole (LTQ) ion trap mass spectrometer (Thermo Scientific, San Jose, CA) was used for LC-MS-MS analysis. The HPLC column was a self-packed 8-cm×75-µm Phenomenex Jupiter C18 reverse phase capillary HPLC column. Samples (10 µl) were injected onto the column and eluted with an acetonitrile, 0.05% acetic acid gradient at a flow rate of 0.2 µl/min. The eluted peptides were directly introduced into the ion source of the mass spectrometer, which was operated at 3.5 kV. The instrument was operated in a data-dependent manner in which full mass spectra (300–2000 Da) were acquired to determine molecular weights, and the four most abundant ions were selected for precursor ion mass tolerance, 2.0 Da; fragment mass tolerance, ±2.0 Da.

Pathway and Network Analysis—Pathway analysis to identify biological networks associated with hyperhomocysteinemia was performed using Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Mountain View, CA). Pathway and network analysis aids the interpretation of the relationships between the 2-D DIGE-identified proteins and facilitates the identification of relatively low abundance proteins that may be missed by 2-D DIGE analysis. The data set consisting of the differentially expressed proteins identified by 2-D DIGE was uploaded into the IPA Knowledge Database, which mapped the proteins (gene/gene products) to global molecular networks to identify focus genes/gene products that are known to directly interact with other gene products in the database. Canonical pathway analysis revealed the biological pathways, networks, and diseases associated with the 2-D DIGE-identified proteins.

Statistics—All results were expressed as mean ± S.D. in all cases, non-paired two-tailed Student’s t tests or one-way analysis of variance were used to determine significance of the DIGE results, and false discovery rates were applied to all comparisons. Fisher’s exact test was used by IPA to determine the p values for all of the network and pathway analyses. In all cases, a p value ≤0.05 was considered statistically significant.

RESULTS

Total Plasma Homocysteine in CBS-deficient Mice—As expected both the HM diet and CBS deficiency resulted in significantly elevated tHcy (Fig. 2A). A small, but significant increase was seen in the CBS-deficient mice on the control diet (CBS−/−, C) versus wild-type animals (CBS+/+, C) (4.27 ± 0.27 μM (n = 4) versus 3.15 ± 0.35 μM (n = 6), respectively, p ≤ 0.05). However, exposure to the HM diet resulted in a 3-fold increase in tHcy in wild-type animals (CBS−/−, HM = 10.7 ± 2.24 μM (n = 6), p ≤ 0.05), and ~20-fold increase in tHcy in CBS−/− mice (CBS−/−, HM = 61.45 ± 17.46 μM (n = 4), p ≤ 0.05) (Fig. 2A). Thus, there is a dramatic gene-nutrient effect on plasma tHcy levels in this model.

It is important to point out that all four animal groups in this study were composed of both male and female animals. Because the number of each gender within each group was low (between n = 2 and n = 4) any specific sex-related influence on plasma or liver Hcy could have been masked. Recently, it was reported that female mice have higher levels of plasma tHcy compared with males, and this difference was attributed to lower CBS activities in the female kidney (32). In the current study, there was a non-significant trend (p = 0.18) toward higher plasma tHcy levels in the female mice; however, larger animal numbers are needed to confirm this observation. When plasma tHcy levels were measured in a larger colony of CBS−/− and CBS−/− mice (n = 96) fed either the control or HM diet, the effect of sex on tHcy was somewhat stronger but still not statistically significant (p = 0.07; data not shown).

Total Liver Homocysteine, Cysteine, Glutathione, and Cysteinyl-glycine in CBS-deficient Mice—Liver concentrations of Hcy were significantly elevated (Fig. 2B) in the CBS-deficient mice regardless of diet (CBS−/−, C = 1.39 ± 0.15 nmol/mg of protein (n = 6) versus CBS−/−, C = 2.68 ± 0.44 nmol/mg of protein (n = 4) and CBS−/−, HM = 2.7 ± 0.22 nmol/mg of protein (n = 4); p ≤ 0.05). The hepatic levels of Hcy did not change in the wild-type CBS−/− mice on the HM diet. Neither Cys (Fig. 2C) nor Cys-Gly (Fig. 2E) levels changed in any group. However, GSH levels were significantly decreased in the CBS-deficient mice on the control diet (CBS−/−, C =
332 ± 88 nmol/mg of protein (n = 6) versus CBS+/−, C = 266 ± 5 nmol/mg of protein (n = 4); p ≤ 0.05 (Fig. 2D). Surprisingly, when the CBS+/− mice were administered the HM diet, GSH levels normalized, suggesting that even when only one CBS allele is mutated there is still an increased flux of Hcy through the transsulfuration pathway, allowing for increased GSH production (Fig. 2D).

**Thiol Stability**—The percentage of L-Cys, L-Hcy, and GSH that was recovered 24 h posthomogenization (and two freeze-thaw cycles) was 88, 72, and 99%, respectively, (supplemental Fig. S1). After 96 h of storage and three freeze-thaw cycles, there was no additional loss in L-Cys or L-Hcy. GSH showed a small, but non-significant additional loss in the 96-h sample compared with the 24-h sample (92 versus 99%). Perhaps the losses were less than anticipated (26, 27) because immediately following homogenization the samples were centrifuged and the aliquot to be used for total thiols was removed, treated with 50 mM disodium EDTA containing 1 mM dithioerythritol, and stored at −80 °C.

**2-D DIGE Validation**—Approximately 2500 spots were detected on each of five gels. The fluorescent images from a representative gel are shown in supplemental Fig. S2. Twenty-four random spots (1% of the total spots detected) were selected for statistical analysis of their Cy2, Cy3, and Cy5 pixel intensities (supplemental Fig. S3). Graphs of the raw pixel volumes and normalized spot volumes for the 24 spots are shown in supplemental Figs. S4 and S5. Importantly, there is no significant difference between the fluorescence emission, expressed either as pixel volume or normalized volume, for any particular protein (supplemental Table S1). However, in several instances, the Cy5 output was slightly (although not significantly) greater than the Cy3 output for the same spot (supplemental Figs. S4 and S5). The Cy5 versus Cy3 variation is due to a small difference in the extinction coefficient for Cy5. For this reason, the manufacturer recommends that within any particular experimental group some samples should be labeled with Cy3 and some should be labeled with Cy5. The intra-assay coefficient of variation was found to be 18–19%, and the inter-assay coefficient of variation varied from 9 to 19% (supplemental Table S2). These results confirm that the Cy2-, Cy3-, or Cy5-labeled spots from the same sample are exactly overlaid and co-detected, and there is no significant difference in the fluorescence output between any given spot pair.

**Identification of Differentially Expressed Proteins in Livers of CBS-deficient Mice by 2-D DIGE**—2-D DIGE coupled with LC-MS-MS identified nine proteins whose expression levels were significantly changed (p ≤ 0.05 and ± 2-fold change) as a result of genotype, 27 proteins whose expression levels...
changed solely as a function of diet, and 14 proteins whose levels changed when both the CBS mutation and HM diet were present (Tables I and II). The positions and identifications of the differentially expressed proteins are shown in Fig. 3, and the IPA-identified metabolic pathways associated with those proteins are shown in Fig. 4. The CBS⁺⁻ genotype altered the expression of proteins involved in 1) homocysteine metabolism (SAHH), 2) arginine and nitrogen metabolism (Nit protein 2 (NIT2), arginase 1 (ARG1), and carbamoyl-diphosphate synthetase 1 (CPS1)), 3) selenoamino acid metabolism (SELENBP1), 4) glutamate metabolism (CPS1), 5) proteolysis (cytosolic nonspecific dipeptidase 2 (CNDP2)), 6) lipid transport (phosphatidylethanolamine-binding protein 1 (PEBP1)), and 7) transcription (enolase (ENO1)) (Figs. 3 and 4 and Table III). The HM diet further increased the number of proteins altered the expression of proteins involved in the response of the cell to oxidative stress (peroxiredoxins 1 (PRDX1) and 2 (PRDX2), thioredoxin (TXN), and epoxide hydrolase 2 (EPHX2)), protein folding and proteolysis (heat shock protein 90, α (HSP90AA) and proteosome 28 subunit α (PSME1)), and molecular transport (SELENBP1, PEBP1, and albumin (ALB)) (Table III). Although the expression of ARG1 was down-regulated in the CBS⁺⁺/+ mice on the C diet, its expression was unchanged when those animals were placed on the HM diet (Table I). A similar normalization occurred with proteins involved in transport and the response of the cell to oxidative stress (Table I). Importantly, TXN was down-regulated in both HM diet groups compared with wild-type controls (Table I), and fatty acid-binding protein 1 (FABP1) showed a 4-fold decrease in expression in the CBS⁺⁺/+ animals on the HM diet. Although FABP1 expression was normal in the CBS⁺⁻/+ mice on the control diet, the lipid transport protein PEBP1 was significantly reduced in that group. Western blot analysis and ELISAs for SAHH, BHMT, and GNMT were performed to validate the 2-D DIGE results and are described below.

### Table I

| Protein name | Gene | gi (accession no.) | CBS⁺⁻ vs. CBS⁺⁺/+ | CBS⁺⁻ vs. CBS⁺⁺/+ HM | CBS⁺⁺/+ vs. CBS⁺⁺/+ HM |
|--------------|------|---------------------|--------------------|----------------------|------------------------|
| SAHH | AHCY | 15929766 | 2.07 | 2.24 | 2.22 |
| Nit protein 2 | NIT2 | 12963555 | 2.26 | 2.35 | 3.13 |
| Selenium-binding protein 1 | SELENBP1 | 285016 | 2.53 | 2.09 | |
| Enolase 1 | ENO1 | 12963491 | 2.2 | |
| Cytosolic nonspecific dipeptidase 2 | CNDP2 | 31981273 | 2.15 | |
| Carbamoyl-diphosphate synthetase 1 | CPS1 | 62533156 | 2.83 | 2 | |
| Arginase 1 | ARG1 | 7106255 | -2.7 | |
| Phosphatidylethanolamine-binding protein 1 | PEBP1 | 53236978 | -2.38 | 2.87 | |
| Major urinary protein | LOC100129193 | 13654245 | -2.4 | |
| Argininosuccinate lyase | ASL | 19269866 | 2.45 | 2.7 | |
| Aldehyde dehydrogenase 9 | ALDH9A1 | ALDH9A1 | 2.64 | 2.5 | |
| Aldehyde dehydrogenase 2 | ALDH2 | 13529509 | 2.7 | 2.52 | |
| Epoxide hydrolase 2 | EPHX2 | 31982393 | 2.14 | 3.53 | |
| Fructose-1,6-bisphosphatase 1 | FBP1 | 6688689 | 3.05 | 2.42 | |
| Glycine N-methyltransferase | GNMT | 15679953 | 2.18 | 2.02 | |
| Betaine-homocysteine methyltransferase | BHMT | 62533211 | 2.1 | |
| 10-Formyltetrahydrofolate dehydrogenase | ALDH1L1 | 20380027 | 2.7 | 3.36 | |
| Malate dehydrogenase 1 | MDH1 | 319837 | 2.31 | 2.02 | |
| Proteosome 28 subunit α | PSME1 | 6755212 | 2.18 | 2.17 | |
| Albumin | ALB | 3647327 | 2 | |
| Regucalcin | RGN | 6677739 | 2.43 | |
| Annexin A5 | ANXA1 | 6753060 | 2.3 | |
| Ferritin light chain 1 | FTL | 6753914 | 3.09 | |
| Peroxiredoxin 1 | PRDX1 | 56103807 | 2.87 | |
| Peroxiredoxin 2 | PRDX2 | 31560539 | 2 | |
| Farnesyl-diphosphate synthetase | FDPS | 182398 | 2.17 | |
| Thioredoxin 1 | TXN | 6755911 | -2.2 | -2.17 | |
| β-Actin | ACTB | 6671509 | 2.35 | |
| Glyoxalase 1 | GLO1 | 31981282 | 2.04 | |
| Heat shock protein 90, α | HSP90AA | 6754254 | 2.12 | |
| 6-Phosphogluconolactonase | PGLS | 13384778 | 2.45 | |
| Fatty acid-binding protein 1 | FABP1 | 2894517 | -4.87 | |

The Nutrigenetics of Hyperhomocysteinemia
Glycine N-Methyltransferase and Betaine-homocysteine Methyltransferase—GNMT and BHMT were found to co-migrate in one of the differentially up-regulated protein spots (Figs. 3 and 5). To determine which of the two proteins was responsible for the increased expression, the level of GNMT was determined by ELISA, and BHMT was analyzed by Western blot (Fig. 6). The ELISA results demonstrated that GNMT was significantly elevated in the wild-type mice on the HM diet (Fig. 6A). GNMT was also elevated (but not significantly) in the CBS-deficient mice on the HM diet; however, genotype alone did not result in a significant increase in GNMT (Fig. 6A). Western blot analysis of the pooled samples from each group showed an increase in BHMT protein in response to diet and genotype when compared with wild-type control mice (Fig. 6C). Thus, GNMT expression increased only in response to diet, whereas BHMT expression increased in response to diet and CBS deficiency.

S-Adenosylhomocysteine Hydrolase—Proteomics analysis demonstrated that SAHH was up-regulated in all three experimental groups, suggesting that SAHH is regulated by both genotype and diet (Table I and Fig. 5). To confirm the DIGE results, SAHH levels were measured using an ELISA as described under “Experimental Procedures” (Fig. 6). ELISA confirmed the results found by 2-D DIGE whereby hepatic SAHH levels were significantly increased in response to diet and genotype (Fig. 6B).

Arginase and Nitric Oxide—As mentioned above, the proteomics analysis showed that ARG1 was significantly decreased by 2.7-fold in the CBS+/− mice on the normal diet. Western blot analysis confirmed the 2-D DIGE results; however, the blots also indicated that ARG1 was decreased in the CBS+/− mice on the HM diet (Fig. 6D), and this result was not seen in the proteomics analysis. Total nitrate and nitrite were significantly increased in the CBS+/− mice (Fig. 2F); this may be the result of the decrease in ARG1 expression.

Network Analysis—To identify signaling pathways involved in hyperhomocysteinemia, we carried out network analysis on the differentially expressed proteins using IPA software. The predominant network associated with the CBS+/− genotype is shown in Fig. 7A. Only the thyroid hormone receptor/rei-
noid X receptor (RXR) pathway was significantly associated with the CBS genotype, whereas the HM diet was associated with four different signaling cascades, namely the NRF2-mediated oxidative stress response, aryl hydrocarbon receptor signaling, lipopolysaccharide/IL-1 mediated inhibition of RXR function, and xenobiotic metabolism signaling (Fig. 7). RXR is involved in xenobiotic metabolism by regulating the transcription of genes involved in GSH biosynthesis and utilization (33). Interestingly, when the CBS+/− mice were placed on the HM diet, the lipopolysaccharide/IL-1 signaling cascade, which is an inhibitor of thyroid hormone receptor/RXR activation, was activated (33) (Fig. 7B).

**DISCUSSION**

In classical homocystinuria produced by mutations in the CBS gene, fatty liver disease is a common finding (6, 8, 34, 35). However, fatty liver disease is also associated with non-gene-induced hyperhomocysteinemia (36–40). Although liver disease has been associated with alterations in methionine metabolism since the 1940s (41, 42) and with homocysteine
metabolism since the 1960s (6, 8), the exact mechanism(s) involved in homocysteine-induced liver injury is still unclear despite many years of study in experimental animal models and in subjects with chronic liver disease (36–38, 43–49). There is considerable evidence suggesting that homocysteine-induced endoplasmic reticulum and oxidative stress mediates the liver injury by promoting apoptosis, inflammation, insulin resistance, and dysregulated lipid metabolism (46, 47, 50). In this study, we used expression proteomics and pathway analysis to dissect and differentiate the metabolic and signaling pathways involved in gene-induced and/or diet-induced hyperhomocysteinemia. We found that hyperhomocysteinemia, whether caused by CBS deficiency or HM diet, alters the abundance of several liver proteins and metabolites involved in homocysteine/methionine metabolism, nitrogen and lipid metabolism, and oxidative stress.

In CBS-deficient animals on a control diet, six proteins were identified with increased expression (SAHH, NIT2, SELENBP1, ENO1, CNDP2, and CPS1), and three were identified with decreased expression (ARG1, PEBP1, and LOC100129193). Surprisingly, SAHH was the only methionine cycle enzyme whose expression was changed in the CBS+/− mice. SAHH is the only reversible enzyme in the cycle, and based on the equilibrium constant ($K_{eq} = 1 \mu M$) for this reaction, S-adenosylhomocysteine (SAH) formation should be favored over SAH hydrolysis (51). However, SAH hydrolysis occurs more frequently in vivo because the breakdown products, Hcy and adenosine, are rapidly removed downstream by methionine synthase, BHMT, CBS, adenosine deaminase, and adenosine kinase. In the CBS+/− mice, however, the transsulfuration pathway is compromised, resulting in increased levels of intracellular Hcy and plasma tHcy (Fig. 2A). Thus, it is postulated that the liver responds to increased intracellular Hcy by inducing the expression of SAHH. In fact, SAHH levels were increased in all three groups of hyperhomocysteinemic animals regardless of the underlying cause of hyperhomocysteinemia. S-Adenosylmethionine (SAM), SAH, and adenosine were not measured in the present study but need to be determined to correlate the SAHH expression with the actual SAH levels and SAM/SAH ratio because SAH is a

### Table III

| Protein name                        | Biological function | Molecular function                  |
|-------------------------------------|---------------------|-------------------------------------|
| SAH hydrolase                       | Hcy metabolism      | Hydrolase, copper binder            |
| Nit protein 2                       | Nitrogen metabolism | Nitrilase                            |
| Selenium-binding protein 1          | Protein transport   | Selenium binder                      |
| Enolase 1                           | Negative regulator of transcription | Transcription factor               |
| Cytosolic nonspecific dipeptidase 2 | Proteolysis         | Carboxypeptidase, zinc binder        |
| Carbamoyl-diphosphate synthetase 1 | Urea cycle          | Nucleotide binder                    |
| Arginase 1                          | Urea cycle          | Hydrolase, manganese binder          |
| Phosphatidylethanolamine-binding protein 1 | Transporter | Lipid binder, nucleotide binder      |
| Major urinary protein               | Transporter         | Pheromone binding, odorant           |
| Argininosuccinate lyase             | Urea cycle          | Catalytic lyase                      |
| Aldehyde dehydrogenase 9           | Aldehyde metabolism | Oxidoreductase                       |
| Aldehyde dehydrogenase 2           | Carbohydrate metabolism | Oxidoreductase               |
| Epoxide hydrolase 2                 | Prostaglandin synthesis, oxidative stress | Hydrolase                   |
| Fructose-1,6-bisphosphatase 1       | Carbohydrate metabolism | Phosphatase          |
| Glycine N-methyltransferase         | Protein modification | Transferase, folate binder           |
| Betaine-homocysteine methyltransferase | Hcy metabolism      | Methyltransferase                    |
| 10-Formyltetrahydrofolate dehydrogenase | One-carbon metabolism | Methyltransferase                    |
| Malate dehydrogenase 1             | Carbohydrate metabolism | Oxidoreductase, NAD binder          |
| Proteosome 28 subunit α             | Proteosome activator | Protein binder                       |
| Albumin                            | Transport            | Binding protein                      |
| Regucalcin                         | Calcium homeostasis  | Calcium binder, enzyme activity      |
|                                    |                     | regulator                         |
| Annexin A5                         | Antiapoptosis, blood coagulation | Phospholipase inhibitor               |
| Ferritin light chain 1              | Iron transport and hemostasis | Oxidoreductase, iron binder            |
| Peroxiredoxin 1                    | Oxidative stress response | Oxidoreductase, antioxidant          |
| Peroxiredoxin 2                    | Oxidative stress response | Oxidoreductase, antioxidant          |
| Farnesyl-diphosphate synthetase     | Cholesterol biosynthesis | Transferase                       |
| Thioredoxin 1                      | Redox homeostasis   | Thiol disulfide exchange, ribonucleotide reduction |
| β-Actin                            | Motility             | Cytoskeletal structure              |
| Glyoxalase 1                       | Carbohydrate metabolism | Lyase                          |
| Heat shock protein 90, α            | Protein folding, mitochondrial transport | Nucleotide binder               |
| 6-Phosphogluconoalactonase          | Carbohydrate metabolism | Hydrolase                   |
| Fatty acid-binding protein 1        | Fatty acid metabolism | Lipid transport                     |
feedback inhibitor of its own synthesis by SAHH (52, 53). Furthermore, SAH is an end product inhibitor of a number of methyltransferases that are involved in its production from SAM, thereby regulating the SAM/SAH ratio (54). Finally, adenosine can dramatically affect SAHH activity as demonstrated by the adenosine analogs, which are potent inhibitors of SAHH activity (55) and are widely used as antiviral, antiparasitic, antiarthritic, and chemotherapeutic drugs because of their effect on gene expression, cell cycle, differentiation, and apoptosis (51, 55). Interestingly, IPA confirmed that proteins involved in cell cycle and differentiation were most affected by hyperhomocysteinemia.

The liver proteome of the wild-type and CBS-deficient animals on the HM diet was dramatically different from those on a control diet. When CBS+/− mice were fed the HM diet for 2 weeks, 26 proteins were up-regulated, and one protein was down-regulated. In addition to SAHH, two additional enzymes of the methionine cycle were up-regulated, namely GNMT and FIG. 5. The effect of hyperhomocysteinemia on methionine cycle proteome. A, 2-D DIGE images of the spots identified by LC-MS-MS as SAHH, BHMT, and GNMT. BHMT and GNMT co-migrated as a single spot. Quantitation of the normalized spot volumes for SAHH (B) and BHMT/GNMT (C) is shown. SAHH was significantly increased in response to CBS genotype and HM diet, whereas the BHMT/GNMT spot was increased only in the HM diet groups. The Cy3 and/or Cy5 spot volumes of each sample were normalized to the spot volume for the Cy2-labeled internal standard and are expressed as mean ± S.D. *, p ≤ 0.05 versus (+/+) C; n = 4–6 animals per group. Error bars indicate ± 1 S.D.
BHMT. GNMT is an abundant hepatic protein whose physiological roles include regulation of the SAM/SAH ratio (56) and control of methyl group synthesis via the folate-dependent one-carbon pool (56–58). Its activity is directly proportional to the level of methionine in the diet (59–61) and inversely proportional to the level of dietary folate (62, 63). It is allosterically inhibited by 5-methyltetrahydrofolate pentaglutamate (56–58). In the present study, both the C and HM diets contained adequate supplies of folate. Thus, the increase in GNMT was a direct consequence of the HM diet. Interestingly, a second major folate-binding protein was up-regulated in the mice on the HM diet, namely 10-formyltetrahydrofolate dehydrogenase, suggesting the possibility that GNMT levels were up-regulated because their inhibitor, 5-methyltetrahydrofolate dehydrogenase, was bound to 10-formyltetrahydrofolate dehydrogenase. BHMT comprises 1% of total liver protein (64), and paradoxically its activity has been shown to increase in response to both a methionine-deficient and a methionine-rich diet (65). However, Park and Garrow (66) noted that BHMT activity is influenced more by dietary choline and/or betaine than methionine. In the present study, the dietary contents of choline and betaine were sufficient; therefore, the BHMT up-regulation was solely the result of the HM diet.

The methionine cycle enzymes were not the only proteins whose expression levels were differentially regulated by hyperhomocysteinemia. Several enzymes involved in nitrogen metabolism and the urea cycle also changed in response to the CBS mutation and/or HM diet. High protein diets generally result in significant increases in the concentrations of the urea cycle enzymes (67) to catabolize the excess nitrogen provided by the diet. Homocystinurics may also be in a state of excess nitrogen as a consequence of their hypermethioninemia. Thus, it seems only natural that the urea cycle enzymes would be up-regulated in all of the groups in the present study. CPS1, an important regulator of the urea cycle, and argininosuccinate lyase (ASL) were both up-regulated in CBS+/− and CBS+/+ mice on the HM diet. However, ARG1 was decreased by 2.7-fold in the CBS+/− animals, and this down-regulation was abolished when those animals were administered the HM diet. Hepatic levels of nitrate and nitrite, the stable end products of NO metabolism, increased in the CBS-deficient ani-

Fig. 6. Validation of DIGE results using ELISA and Western blot analysis. GNMT (A) and SAHH (B) concentrations were measured by ELISA in liver homogenates from wild-type CBS+/− and heterozygote CBS+/− mice after 14 days on a normal diet (C diet) or a diet supplemented with 0.5% methionine in the drinking water (HM diet). Results were normalized to protein concentration and are expressed as mean ± S.D. *, p ≤ 0.05 versus (+/+); n = 4–6 animals per group. In C and D, the pooled homogenates of each experimental group were electrophoresed by 12% SDS-PAGE, and BHMT and arginase were detected by Western blot, respectively. Error bars indicate ± 1 S.D.
The Nutrigenetics of Hyperhomocysteinemia

A.

Key: ♦ Enzyme; □ Kinase; □ Receptor; △ Cytokine/growth factor

B.

-TR/RXR Activation
-NRF2-mediated Oxidative Stress Response
-Aryl Hydrocarbon Receptor Signaling
-LPS/IL-1 Mediated Inhibition of RXR Function
-Xenobiotic Metabolism Signaling
mals, and those levels normalized when the CBS+/- mice were placed on the HM diet (Fig. 2F). Because ARG1 competes with nitric oxide synthase (NOS) for available arginine, the decrease in ARG1 in the CBS+/- animals should result in increased NOS activity and NO synthesis. But is increased hepatic NO beneficial or detrimental? The general view is that NO protects the vasculature by promoting vascular relaxation and preventing endothelial dysfunction, but in the liver it has been shown to potentiate oxidative injury via the formation of peroxynitrite in ischemia-reperfusion injury (68–70), alcoholic liver disease (71), and acetaminophen-induced hepatotoxicity (72). Thus, the decrease in ARG1 and increase in NO in the CBS+/- mice may be indicative of early liver damage.

The increase in hepatic NO in the current study is in direct contrast to what has been described in the vasculature. In studies using cultured endothelial cells, bioavailable NO was significantly decreased in Hcy-treated cells (17, 73, 74). Also, in aortic rings from hyperhomocysteinemic mice, Lentz and co-workers (18, 75, 76) demonstrated that maximal relaxation was significantly impaired in CBS+/- mice fed a low folate or high methionine diet. One explanation is that homocysteine alters the cellular redox status, resulting in the generation of ROS such as hydrogen peroxide and superoxide, which in turn oxidatively inactivate endothelium-derived NO (15, 17, 18, 22). Tyagi et al. (74) proposed a mechanism for homocysteine-induced oxidative stress in microvascular endothelial cells whereby Hcy activates protease-activated receptor 4, which then increases the expression of NADPH oxidase, reduces the expression of TXN, and results in the production of reactive oxygen species. Studies by Loscalzo and co-workers (22, 77) have confirmed that Hcy is associated with increased superoxide generation and a decrease in the antioxidant enzyme glutathione peroxidase 1 (GPx-1). In the present study, GPx-1 expression was not changed; however, total GSH was significantly decreased in the CBS+/- mice.

Because hyperhomocysteinemia is an important source of oxidative stress and because hepatic GSH was significantly decreased in the CBS+/- mice, one might predict the need for up-regulation of the antioxidant enzymes. However, none of the usual candidate enzymes (i.e., GPx-1, superoxide dismutase, or catalase) were changed in the CBS+/- mice. On the other hand, the expression levels of three antioxidant enzymes, namely PRDX1, PRDX2, and TXN, were altered in response to the HM diet. PRDX1 and -2 were significantly increased by 2.87- and 2-fold, respectively, in the wild-type mice, whereas TXN was significantly down-regulated by -2.2- and -2.17-fold in the CBS+/- and CBS+/- on the HM diet, respectively. TXN is a 12-kDa oxidoreductase that can reduce, form, or isomerize protein disulfide bonds as well as scavenge singlet oxygen and hydroxyl radical (78, 79). PRDX1 and -2 belong to the antioxidant family of peroxidases, and they protect the cell from ROS by reducing a wide range of hydroperoxides. TXN maintains PRDX1 and -2 in their active reduced states by serving as an electron donor to reduce their corresponding oxidized forms. As mentioned above, Tyagi et al. (74) showed that TXN expression was reduced in Hcy-treated microvascular endothelial cells, and this reduction was associated with a concomitant increase in protease-activated receptor 4, NADPH oxidase, ROS, and inducible NOS, and a reduction in endothelial NOS. Also, wild-type CBS mice on the HM diet were able to up-regulate the expression of PRDX1 and -2, possibly as a consequence to the decreased TXN expression, but the CBS+/- mice were unable to increase either PRDX, although they too exhibited low TXN levels. Thus, the CBS+/- mice may be at an even greater risk for oxidative liver injury. It is possible that the plasma tHcy levels were too low in the CBS+/- mice on the control diet (tHcy = 4.27 µM) to trigger this response, whereas plasma tHcy in the wild-type and CBS+/- mice on the HM diet (tHcy: C (+/+) = 10.7 µM; C (+/-) = 61.45 µM) were sufficiently elevated to initiate the events leading to the oxidative stress response. Interestingly, IPA analysis confirmed that the wild-type mice on the HM diet did activate an NFR2-mediated oxidative stress response, whereas the CBS+/- mice did not (Fig. 7B).

In summary, we used a quantitative proteomics approach to identify hepatic proteins whose expression levels were changed as a consequence of hyperhomocysteinemia, whether the hyperhomocysteinemia was induced by a genetic mutation in CBS or by a high methionine diet. Although there were a few similarities between the two proteomes, there were many more differences. Nine proteins were changed response to genotype, whereas 27 proteins changed in response to diet. SAHH was up-regulated in both groups, but the HM diet caused a further increase in GNM and BHMT. Many proteins involved in nitrogen and urea metabolism were up-regulated in the diet group; however and importantly, ARG1 was down-regulated and NO was increased in the CBS mutants. Finally, several proteins involved in the response of the cell to oxidative stress were up-regulated in wild-type mice in response to diet (PRDX1, PRDX2, and HSP90AA) but not in the CBS mutants, and total GSH levels were significantly decreased in the CBS+/- mice. Taken together, these results suggest that in heterozygous CBS-deficient mice the liver may be at an increased risk for homocysteine-induced oxidative stress.

**Fig. 7. Network analysis of CBS-regulated proteins.** A, direct (solid lines) and indirect (dashed lines) protein-protein interactions between the up-regulated (gray) and down-regulated (black) hepatic proteins of the CBS+/- mice and members of the extracellular signal-regulated protein/mitogen-activated protein kinase (ERK/MAPK) signaling cascade. Solid lines indicate simple binding associations between proteins, whereas arrowed lines indicate that the protein nearest to the arrowhead is being acted upon by the protein furthest from the arrowhead. B, the top function(s) associated with the CBS genotype (black bar), the HM diet (white bar), and CBS+/- mice on the HM diet (gray bar). TR, thyroid hormone receptor.
The Nutrigenetics of Hyperhomocysteinemia

oxidative damage, and this is further compounded when an HM diet is introduced.

* This work was supported, in whole or in part, by National Institutes of Health Grants HL 52234 (to D. W. J.) and HL 063943 and NS024621 (to S. R. L.) from the NHLBI. This work was also supported by American Heart Association Grant AHA 08600052Z (to S. D.).

[5] The on-line version of this article (available at http://www.mcponline.org) contains supplemental Figs. S1–S5 and Tables S1 and S2.

† Present address: Oklahoma Medical Research Foundation, Oklahoma City, OK 73104.

‡‡ To whom correspondence should be addressed: Dept. of Cell Biology, NC-10, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195. Fax: 216-444-9404; E-mail: jacobsd@ccf.org.

REFERENCES

1. Finkielstein, J. D., and Martin, J. J. (1984) Methionine metabolism in mammals. Distribution of homocysteine between competing pathways. J. Biol. Chem. 259, 9508–9513

2. Reed, M. C., Nijhout, H. F., Sparks, R., and Ulrich, C. M. (2004) A mathematical model of the methionine cycle. J. Theor. Biol. 226, 33–43

3. Storch, K. L., Wagner, D. A., Burke, J. F., and Young, V. R. (1989) Quantitative study in vivo of methionine cycle in humans using [methyl-2H3] and [1–13C]methionine. Am. J. Physiol. Endocrinol. Metab. 255, E232–E233

4. Stead, L. M., Brosnan, M. E., and Brosnan, J. T. (2000) Characterization of homocysteine metabolism in the rat liver. Biochem. J. 350, 685–692

5. Christensen, B., Refsum, H., Vintermyr, O., and Ueland, P. M. (1991) Homocystinuria: an export from cells cultured in the presence of physiological or superfluous levels of methionine: methionine loading of non-transformed, transformed, proliferating, and quiescent cells in culture. J. Cell. Physiol. 146, 52–62

6. Carson, N. A., Dent, C. E., Field, C. M., and Gaull, G. E. (1965) Homocystinuria: clinical and pathological review of ten cases. J. Pediatr. 66, 565–583

7. Jacobsen, D. W., Gatautis, V. J., Green, R., Robinson, K., Savon, S. R., Secic, M., Ji, J., Otto, J. M., and Taylor, L. M., Jr. (1994) Rapid HPLC methods for plasma homocysteine by high-performance liquid chromatography with fluorescence detection. Anal. Biochem. 178, 208–214

8. McCully, K. S. (1969) Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am. J. Pathol. 66, 111–128

9. Mudd, S. H., Finkielstein, J. D., Irreverve, F., and Laster, L. (1984) Homocysteinuria: an enzymatic defect. Science 143, 1443–1445

10. Mudd, S. H., Levy, H. L., and Kraus, J. B. (2001) Disorders of transulfuration, in The Metabolic and Molecular Bases of Inherited Disease. (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D.), McGraw-Hill Inc., New York

11. Refsum, H., Frikken, A., Meyer, K., Ueland, P. M., and Kase, B. F. (2004) Plasma concentrations of homocysteine and other thiols in healthy men. Can. J. Physiol. Pharmacol. 92, 1585–1589

12. Hanssen, B. M., Heath, S. H., Kim, S., Suh, J. H., and Hagen, T. M. (2008) Augmented activity of renal cystathionine β-synthase: implications for sex-dependent differences in plasma homocysteine levels. Am. J. Physiol. Renal Physiol. 293, F594–F600

13. Watanabe, M., Osada, J., Aratani, Y., Kuckmann, K., Reddick, R., Malinow, M. R., and Maeda, N. (1995) Mice deficient in cystathionine β-synthase: animal models for mild and severe homocysteinemia. Proc. Natl. Acad. Sci. U.S.A. 92, 1071–1075

14. Ventura, P., Rosa, M. C., Abbati, G., Marchini, S., Grandone, E., Vergura, P., Destefanis, S., and Zeneroli, M. L. (2003) Hyperhomocysteinemia in 484 Molecular & Cellular Proteomics 9.3
chronic liver diseases: role of disease stage, vitamin status and methyl-eneptathydrofollate reductase genetics. Liver Int. 25, 49–56
38. Gulsen, M., Yesilova, Z., Bagic, S., Uygun, A., Ozcan, A., Erzin, C. N., Erdil, A., Sanisoglu, S. Y., Cakir, E., Ates, Y., Erbil, M. K., Karaenen, N., and Dagalk, K. (2005) Elevated plasma homocysteine concentrations as a predictor of steatohepatitis in patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 20, 1448–1455
39. Herrero, J. I., Quiroga, J., Sangro, B., Beloqui, O., Pardo, F., Cienfuegos, J. A., and Prieto, J. (2000) Hyperhomocysteinemia in liver transplant recipients: prevalence and multivariate analysis of predisposing factors. Liver Transpl. 6, 614–618
40. Woo, C. W., Prathapasinghe, G. A., Siow, Y. L., and O, K. (2006) Hyperho- mocysteinemia induces liver injury in rats: protective effect of folic acid supplementation. Biochim. Biophys. Acta 1762, 656–665
41. Kinsell, L. W., Harper, H. A., Barton, H. C., Michaels, G. D., and Weiss, H. A. (1947) Rate of disappearance from plasma of intravenously administered methionine in patients with liver damage. Science 106, 589–590
42. Kinsell, L. W., Harper, H. A., Barton, H. C., Hutchin, M. E., and Hess, J. R. (1948) Studies in methionine and sulfur metabolism. I. The fate of intravenously administered methionine in normal individuals and in patients with liver damage. J. Clin. Invest. 27, 677–688
43. Kaplowitz, N., and Ji, C. (2006) Rats fed prolonged high protein diets show an increase in nitric oxide metabolism and liver megamitochondria. Arch. Bio- chem. Biophys. 258, 426–435
44. Lee, V. G., Johnson, M. L., Baust, J., Laubach, V. E., Watkins, S. C., and Billar, T. R. (2001) The roles of INOS in liver ischemia-reperfusion injury. Shock 16, 355–360
45. Zima, T., Safarova, T., Hirta, K., Kimura, H., Nagayama, M., and Matsuno, T. (1999) Beneficial effects of inducible nitric oxide synthase inhibitor on reperfusion injury in the pig liver. Transplantation 68, 803–813
46. Hirschi, S., Poniachick, J., Avendano, M., Csendes, A., Bundles, P., Smok, G., Diaz, J. C., and de la Maza, M. P. (2007) 5-Methyltetrahydrofolate is bound in intersubunit betaine-homocysteine methyltransferase activity by folate derivatives: implications for regu- lation of methionine synthase. J. Biol. Chem. 282, F671–F678
47. Finkelstein, D. J. (2000) Methionine metabolism in mammmals. J. Nutr. Bio- chem. 1, 228–237
48. Finkelstein, D. J. (2001) Regulation of homocysteine metabolism, in Homocys- teine in Health and Disease (Carmel, R., and Jacobsen, D. W.) pp. 79–91, Cambridge University Press, Cambridge, UK
49. Finkelstein, J. D., Heistad, D. D., Faraci, F. M., and Lentz, S. R. (2001) Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ. Res. 88, 1203–1209
50. Lentz, S. R., Erger, R. A., Dayal, S., Malinow, M. R., Sigmund, C. D., Heistad, D. D., and Facari, F. M. (2000) Folate dependence of hyperhomocys- teinemia and vascular dysfunction in cystathionine beta-synthase-defi- cient mice. Am. J. Physiol. Heart Circ. Physiol. 279, H970–H975
51. Eberhardt, R. T., Forgue, M. A., Cap, A., Leopold, J. A., Rudd, M. A., Trollet, M., Heydnic, S., Stark, R., Klinga, E. S., Moldovan, N. I., Yag- houbi, M., Goldschmidt-Clermont, P. J., Farber, H. W., Cohen, R., and Loscalzo, J. (2001) Endothelial dysfunction in a murine model of severe hyperhomocysteinemia. J. Clin. Investig. 106, 483–491
52. Ottaviano, F. G., Handy, D. E., and Loscalzo, J. (2008) Redox regulation in the extracellular environment. Circ. J. 72, 1–3550
53. Das, K. C., and Das, C. K. (2000) Thiodoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochem. Biophys. Res. Commun. 277, 443–447